BioSpace News Archive

Nephros, Inc. today announced that it has entered into a definitive agreement to sell its Pathogen Detection Systems (“PDS”) business.

Annovis Bio, Inc. today announced the publication of Phase 2a clinical study data in The Journal of Prevention of Alzheimer’s Disease.

M6P Therapeutics Presents Novel AAV Gene Therapy Approach for the Treatment of Gaucher Disease at the ESGCT 29th Annual Congress.

Selecta Biosciences, Inc. today announced three upcoming presentations, including one joint presentation with our partner AskBio, at the 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference.

PDS Biotechnology Corporation today announced expanded interim data in the Phase 2 clinical trial investigating the PDS0101-based triple combination therapy in advanced human papillomavirus (HPV)-positive cancers.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will be collaborating with NOCD, an organization that facilitates access to online therapy for people with obsessive-compulsive disorder (OCD) through its innovative telehealth platform.

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that it is building on its clinical development science and operations capabilities through recent key appointments.

IRLAB Therapeutics AB announced that Richard Godfrey, CEO of IRLAB, will present the company at Redeye Neurology Seminar and participate in a panel discussion on Wednesday, October 12, 2022.

Pharming Group N.V. announces that it has submitted a Marketing Authorisation Application to the European Medicines Agency for leniolisib, an oral, selective phosphoinositide 3-kinase delta inhibitor, as a treatment for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency, in adults and adolescents 12 years or older.

invIOs GmbH announces its participation at three upcoming industry and investor conferences: BIO-Europe, Inv€$tival Showcase and the Jefferies 2022 London Healthcare Conference.